Malignant Lymphoma Clinical Trial
Official title:
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Recurrent Malignant Lymphoma
The primary objective is to assess the safety and tolerability of JS-001 in subjects with
recurrent malignant lymphoma, and to evaluate its preliminary efficacy.
The secondary objectives are to: 1) characterize the single-dose and multi-dose
pharmacokinetic (PK) profile of JS-001, 2) characterize the immunogenicity of JS-001; 3)
assess the dose-efficacy relationship of JS-001 single agent, and 4) preliminarily evaluate
biomarkers associated with the efficacy of JS-001.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03346096 -
TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma
|
Phase 2 | |
| Completed |
NCT05190263 -
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
|
||
| Completed |
NCT01473095 -
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
|
Phase 1 | |
| Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT02131688 -
Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
|
Phase 1 | |
| Completed |
NCT00892502 -
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
|
N/A | |
| Completed |
NCT00685997 -
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
|
N/A | |
| Not yet recruiting |
NCT06358001 -
EchoTip AcuCore Post-Market Clinical Study
|
||
| Recruiting |
NCT04986293 -
CPAP or BiPAP for Motion Mitigation During Radiotherapy
|
N/A | |
| Completed |
NCT01588548 -
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT04464889 -
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Terminated |
NCT01016795 -
Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma
|
Phase 2 | |
| Completed |
NCT04464590 -
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
|
||
| Recruiting |
NCT04698616 -
Lean Body Mass and Side Effects in Patients With Lymphoma
|
||
| Active, not recruiting |
NCT02678299 -
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
|
Phase 1/Phase 2 | |
| Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
| Completed |
NCT01789060 -
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma
|
N/A | |
| Completed |
NCT05827341 -
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
|
||
| Active, not recruiting |
NCT05515029 -
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
|
Phase 3 | |
| Not yet recruiting |
NCT05545202 -
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
|
Phase 4 |